A new class of ''targeted'' drugs which tackle harmful effects of the menopause without the problems associated with hormone replacement patches could be on sale in Britain within a year.
Known as Serms - Selective oEstrogen Receptor Modulators - they work by targeting selected cells in the body while ignoring others, and were discussed during conference of gynaecologists and osteoporosis experts in Copenhagen, last week.
Hormone replacement therapy involves restoring the hormone oestrogen to the body, but carries the risk of side effects at best unpleasant, at worst dangerous.
Post-menopausal women on HRT often find they return to having monthly periods and suffer breast pain. It has also been claimed it can increase the chances of breast cancer.
But it offers major benefits in preventing osteoporosis - brittle bone disease - and reducing heart disease risks.
The new drugs are designed to stimulate receptors, points of molecular interaction on cells, in the same way as oestrogen. But while oestrogen is indiscriminate, Serms target specific receptors in specific places.
They stimulate receptors in the bone to stop oesteoporosis, and also target the cardio-vascular system to lower the level of fats in the bloodstream.
But, unlike oestrogen, they do not stimulate the uterus to resume bleeding, and they also ignore the cells of the breast.
The drugs were developed by American giant Lilly Industries, which has submitted licence applications in Europe and the US, and hopes to get the go-ahead to market them within a year.
Serms are not expected to replace HRT altogether, as they are not as effective at preventing some of the most common symptoms of the menopause, like flushes and hot sweats.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article